Camurus ABCAMRF -3.57%79 PB Ratio is 6.77 as of Jun. 25, 2026, which is 37% below its 10-year median of 10.78. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Camurus AB ranks worse than 80.37% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Camurus AB's share price is $54.00. Camurus AB's Book Value per Share for the quarter that ended in Mar. 2026 was $7.98. Hence, Camurus AB's PB Ratio of today is 6.77.
Good Sign:
Camurus AB stock PB Ratio (=6.98) is close to 5-year low of 6.3.
The historical rank and industry rank for Camurus AB's PB Ratio or its related term are showing as below:
CAMRF'
s PB Ratio Range Over the Past 10 Years
Min: 4.13 Med: 10.78 Max: 21.89
Current: 6.98
During the past 13 years, Camurus AB's highest PB Ratio was 21.89. The lowest was 4.13. And the median was 10.78.
CAMRF's PB Ratio is ranked worse than 80.37% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs CAMRF: 6.98
During the past 12 months, Camurus AB's average Book Value Per Share Growth Rate was 25.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 58.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 40.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 18.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Camurus AB was 152.00% per year. The lowest was -27.40% per year. And the median was 41.65% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Camurus AB PB Ratio Related Terms
Camurus AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Camurus AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Camurus AB (CAMRF) has a PB Ratio of 6.77 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Camurus AB and its competitors. This is 37% below median its historical median of 10.78. Over the past decade, Camurus AB's PB Ratio has ranged from 4.13 to 21.89. According to the industry distribution chart, Camurus AB ranks #991 out of 1233 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Camurus AB's PB Ratio too high?
Camurus AB's current PB Ratio of 6.77 is 37% below median its 10-year median of 10.78. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 21.89. The Biotechnology industry median PB Ratio is 2.83. Camurus AB's value of 6.77 is 139.2% above this industry median. Based on the distribution chart, Camurus AB ranks #991 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #991 out of 1233 companies for PB Ratio. This places Camurus AB in the lower half of its industry. The industry median PB Ratio is 2.83. Camurus AB's value of 6.77 is 139.2% above this benchmark. Historically, Camurus AB's own PB Ratio has ranged from 4.13 to 21.89 over the past decade. While the company's 10-year median is 10.78 vs. the industry median of 2.83, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current PB Ratio of 6.77 is 139.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current PB Ratio is 6.77, which is 37% below median its own 10-year median of 10.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current PB Ratio is 6.77, which is 37% below median its 10-year median of 10.78 and 139.2% above the Biotechnology industry median of 2.83. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current PB Ratio is 6.77 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
PB Ratio: 6.77 (37% below median its 10-year median of 10.78)
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 139.2% above the Biotechnology median (#991 of 1233)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
